Recombinant Mouse PD-L2/B7-DC protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1842

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse PD-L2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse PD-L2 protein Leu20-Arg219 (Accession# Q9WUL5) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 58205
• Accession: Q9WUL5
• PredictedSize: 48.8 kDa
• SDS-PAGE: 55-70 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Programmed cell death 1 ligand 2 (PDCD1LG2), also known as PD-L2, CD273 and B7-DC, is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PDCD1LG2/PD-L2 protein is expressed mainly by dendritic cells, macrophages, and tumor cells, and down-regulates the effector functions of T cells via PD-1/PD-L2 axis in the tumor microenvironment. The endogenous PDCD1LG2/PD-L2 protein displays a molecular weight of ∼45 kDa(glycosylated form), and a minor band at 35 kDa (non-glycosylated form) in western blot.

References:

1.Takamori S, et al. (2018). Anticancer Res. 38(10):5897-5901.
2.Wang H, et al. (2017). Oncoimmunology. 6(7):e1327494.
3.Xu Y, et al. (2021). J Immunother Cancer. 9(10):e002699.